SCHEMBL4311380

SCHEMBL4311380

CCCN(CCC(C)(C)C)C(=O)Cn1c(=O)c(CC)cc2ccc(OC)cc21

nearest known ligand 0.47

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MAPT P10636 15/20 0.47
THRB P10828 1/20 0.43
TP53 P04637 3/20 0.42
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4310998 0.97 MAPT (0.48) MAPTTHRBTP53
SCHEMBL4315094 0.94 MAPT (0.45) MAPTTHRBTP53
SCHEMBL4323869 0.93 MAPT (0.45) MAPTTHRBTP53
SCHEMBL4303491 0.93 MAPT (0.47) MAPTTHRBTP53
SCHEMBL4318320 0.89 MAPT (0.40) MAPTTHRBTP53LMNA
SCHEMBL4316432 0.89 MAPT (0.41) MAPTTHRBTP53LMNA
SCHEMBL4305278 0.87 LYN (0.42) MAPTTP53LMNA
SCHEMBL4316870 0.87 MAPT (0.50) MAPTTHRBTP53
SCHEMBL4305128 0.86 MAPT (0.47) MAPTTHRBTP53
SCHEMBL4315027 0.85 MAPT (0.46) MAPTTHRBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US claimed
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension MERCK SHARP & DOHME CORP. 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062280-A1 Ophthalmic Compositions for Treating Ocular Hypertension KCNN3, KCNN1, KCNN2 MAPT 498/4885THRB 2231/4885TP53 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.